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Imaging brain circuits in anxiety disorders
Despite the huge burden that anxiety disorders can 
 impose on individuals and social systems, most people, 
having themselves been aﬀ ected by fear at some 
point during their life, intuitively assume that they can 
empathise with anxious patients by merely extrapolating 
the emotion associated with such an experience. Indeed, 
the ease of creating models of anxiety disorders in 
healthy volunteers has rendered the topic approachable 
to researchers from a range of disciplines. A neural 
pathway common to physiological and pathological 
anxiety was suspected long before the Research Domain 
Criteria were announced by the National Institute of 
Mental Health1 and key neurobiological correlates, 
such as the prevailing role of the amygdala and the 
importance of serotonergic modulation, were discovered 
early in studies of fear and anxiety. However, as Oliver 
Robinson and colleagues correctly state in their article 
in The Lancet Psychiatry, study of the function of the 
amygdala alone yields only some insight into the 
pathophysiology of anxiety disorders.2 Approaches 
such as staging, integrating systems involved in anxiety 
processing,3 together with genetic and clinical illness 
variables, promise to be more useful.
The development and widespread use of neuroimaging 
techniques has produced an increasingly diverse picture 
of the involvement of diﬀ erent brain structures and 
neurotransmitter systems in processing of fear. MRI 
allows us to study distinct brain networks. When 
functional connectivity is calculated, these networks 
emerge as regions with correlated activity, measured 
as a blood oxygenation level-dependent signal, over 
a period of time which is supposedly indicative of 
their involvement in processing similar information. 
In the context of anxiety disorders, the regulation 
of the amygdala by the frontal cortex has received 
special attention. Most studies have emphasised the 
disruption of the inhibition of the amygdala by the 
prefrontal cortex in particular anxiety disorders—eg, 
in social anxiety disorder, the connectivity between 
the orbitofrontal cortex and the amygdala is greatly 
impaired.4–6 In their study, Robinson and colleagues have 
focused on the dorsal medial prefrontal cortex, which is 
distinguished from other parts of the prefrontal cortex 
by its increased connectivity with the amygdala, at least 
in generalised anxiety disorder.7 They have shown that 
instead of inhibiting threatening stimuli, the dorsal 
medial prefrontal cortex–amygdala circuit helps their 
ampliﬁ cation. A similar mechanism was ﬁ rst reported 
in rodents8 and translated to anxiety models in healthy 
people.9,10 Now ﬁ nally its role in anxious patients has 
been shown by Robinson and colleagues.2 The ﬁ nding 
aﬃ  rms the view that an intrinsically self-protective circuit 
malfunctions in anxiety disorders.
Despite this promising result, it is premature to 
postulate whether or how the knowledge of this 
mechanism will translate into clinical practice. At this 
point we are presented with a ﬁ nding that adds another 
aspect to our understanding of anxiety disorders and has 
the potential to become a useful biomarker. Nevertheless, 
the results need to be replicated before we can draw ﬁ rm 
conclusions.11 The reference to modiﬁ cation of resting-
state connectivity of the dorsomedial prefrontal cortex 
by selective serotonin reuptake inhibitors in healthy 
volunteers12 might ultimately prove to be misleading 
in hindsight in view of the altered neurobiology of 
anxious patients. We need to ﬁ nd out to what extent the 
diﬀ erences shown allow for the stratiﬁ cation of patients 
to treatments. In view of the long list of statistically 
signiﬁ cant imaging results in diﬀ erent investigations, 
it seems increasingly unlikely that an isolated imaging 
parameter will be suﬃ  cient.13 However, a combination of 
several such markers with replication across modalities 
might ultimately lead to a clinically useful speciﬁ cation of 
illness characteristics and tests.
The next step is to investigate pharmacological 
challenge of this circuit in patients, together with the 
long-term assessment of treatment. Sophisticated 
modelling should be used to assess directionality in 
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network processing (eg, dynamical causal modelling)6 
or more holistic network features (eg, graph theoretical 
approaches).14 Combination with molecular imaging 
with use of PET can provide robust information about 
network changes in neurotransmission associated 
with treatment.15 More causal approaches based 
on transcranial optogenetic inhibition in animal 
models by red light penetrating the skull might show 
the functions of these networks in more detail.16 
Simultaneous investigation of molecular, structural, 
and functional imaging changes together with illness 
variables is likely to increase the speciﬁ city of each 
and result in models with suﬃ  cient predictive values 
for clinical practice. Robinson and colleagues2 present 
a mechanistic understanding of pathological anxiety 
that might contribute to this goal.
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There is no wealth without mental health
Among the proposed transformative shifts in the 
post-2015 development agenda1 are a focus on the most 
vulnerable (leave no one behind) and strengthening 
of economies by inclusion of all who can contribute. 
These issues are at the heart of global mental health, 
now increasingly recognised as having an essential role 
in the achievement of shared development objectives .2 
Mental health was a key theme in the UK International 
Development Parliamentary Select Committee Inquiry 
on Disability and Development,3 and is part of the 
continuing Open Working Group consultations on the 
Sustainable Development Goals. Indeed, discussions 
at the 2014 World Economic Forum in Davos were 
paraphrased as “There is no wealth without mental 
health” on the basis that the worldwide cost of mental 
disorders in 2010 was estimated at US$2·5 trillion, with 
the cost projected to surge to $6·0 trillion by 2030.4 
Fortunately, we now have an increased understanding of 
how to address these disorders in practical ways, including 
in low-resource settings. Over the past decade, global 
mental health research has clariﬁ ed the eﬀ ect that poor 
mental health has on many central issues in development, 
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